Brought to you by 
Kyowa gains Asian rights to bardoxolone from Reata
31 Aug 2018
Executive Summary
Kyowa Hakko Kirin has licensed exclusive rights to develop and sell Reata Pharmaceuticals' (inflammation drugs) bardoxolone in Japan, China, Taiwan, Korea, and Southeast Asian countries.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Contract
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Kyowa gains Asian rights to bardoxolone from Reata
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice